XOMA Royalty Expands Portfolio with Mezagitamab Acquisition
XOMA Royalty Corporation (NASDAQ: XOMA), a key player in biotech royalty aggregation, has made a significant strategic move by acquiring the future royalty and milestone rights for mezagitamab (TAK-079) from BioInvent International. This acquisition represents a transaction worth up to USD $30 million, initiated with an immediate payment of USD $20 million. The investment marks a promising addition to XOMA’s already robust late-stage royalty portfolio.
The Importance of Mezagitamab
Mezagitamab is currently under development and is anticipated to play an essential role in the treatment landscape for various conditions, including its application in cancer therapies. As a fully human IgG1 monoclonal antibody, its high affinity for CD38 expressing cells, such as plasmablasts and plasma cells, gives it the potential to become a leading treatment option. XOMA Royalty aims to leverage this potential through its new acquisition.
Impact on XOMA Royalty’s Strategy
According to Brad Sitko, Chief Investment Officer of XOMA, the acquisition is designed not only to enhance the financial prospects related to mezagitamab but also to reinforce their existing relationship with BioInvent. This partnership dates back to a 2003 agreement, highlighting the legacy technologies that paved the way for mezagitamab’s development. The funding provided to BioInvent enables them to further progress their proprietary pipeline.
BioInvent's Strategic Vision
BioInvent operates with a mission to discover and develop innovative immune-modulatory antibodies targeting cancer. The company’s advanced technology platform, known as n-CoDeR®, has proven invaluable in identifying therapeutic candidates that progress into clinical trials. With the funds acquired from the deal with XOMA, BioInvent is set to bolster its financial standing, providing the necessary stability to enhance its clinical programs.
Long-Term Financial Projections
XOMA Royalty’s future entitlements, including potential milestones of up to USD $16.25 million from Takeda along with mid-single digit royalties on future sales of mezagitamab, reflect a strong outlook for the acquisition. In recent financial updates, Takeda announced the initiation of a Phase 3 clinical trial for mezagitamab, marking a crucial step in its journey toward regulatory approval.
Understanding the Royalty Structure
This acquisition underscores a shifting trend in the biotech industry where companies are increasingly looking at alternative funding sources through innovative partnerships. The structured deal allows XOMA Royalty to reduce its risk while providing BioInvent with the capital necessary for sustained growth. This model exemplifies a collaborative approach in crucial therapeutic developments.
About XOMA Royalty Corporation
XOMA Royalty Corporation plays a unique role in the biotechnology landscape by acquiring future economics tied to pre-commercial and commercial therapeutic candidates. Their model supports biotech companies in attaining their goals for advancing human health without immediate dilution of assets. XOMA continues to build a diverse portfolio, aiming for significant impact in the biotech sector.
About BioInvent International
BioInvent, a Stockholm-listed biotechnology firm, concentrates on novel therapeutic discoveries for cancer treatment. With multiple candidates in various stages of clinical trials, BioInvent's proprietary F.I.R.S.T™ technology plays a crucial role in identifying targets and achieving successful outcomes in drug development. This partnership with XOMA is a promising step in continuing their mission.
Frequently Asked Questions
What is XOMA Royalty Corporation?
XOMA Royalty Corporation is a biotechnology royalty aggregator that specializes in acquiring future economic rights related to therapeutic candidates in development.
What did XOMA acquire from BioInvent?
XOMA acquired the future royalty and milestone rights for the drug mezagitamab, valued at up to USD $30 million.
How will this acquisition benefit XOMA?
This acquisition enhances XOMA's late-stage royalty portfolio, providing potential future revenues from mezagitamab sales and clinical milestones.
What role does Takeda play in this transaction?
Takeda is the company developing mezagitamab, and XOMA will benefit from certain milestone payments and royalties tied to the drug's commercial performance.
How does BioInvent benefit from this deal?
BioInvent receives non-dilutive capital that can be used to further develop its pipeline and enhance its financial stability, supporting its ongoing clinical programs.
